N-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]acetamide | 593959-35-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]acetamide
• 英文别名: N-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide；Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-；N-[5-(3-imidazol-1-yl-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]acetamide
• CAS: 593959-35-4
• 化学式: C₁₆H₁₆N₄O₃S₂
• 分子量: 376.46
• InChiKey: SQWAXHGWLCYBIN-UHFFFAOYSA-N

物化性质

• 熔点：
  293 °C
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  131
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]acetamide 在 硫酸 作用下， 以 乙醇 、 水 为溶剂， 反应 2.25h， 生成 N-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide sulfate salt
  参考文献：
  名称：

  WO2015/162584

  摘要：

  公开号：
• 作为产物：
  描述：

  1-bromo-1-(3-fluoro-4-methanesulfonyl-phenyl)-propan-2-one 在 5-乙基-2-甲基-吡啶 、 potassium carbonate 作用下， 以 N-甲基吡咯烷酮 、 乙腈 为溶剂， 反应 4.08h， 生成 N-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]acetamide
  参考文献：
  名称：

  Development of a Practical Route for the Manufacture of N-[5-(3-Imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]acetamide

  摘要：

  An efficient synthesis of a potent candidate in our respiratory program is described. The synthesis based on a key Darzens condensation-alpha,beta-epoxide rearrangement circumvented the toxicity and safety issues encountered in the original synthesis route. Subsequent functionalization and formation of an heterocyclic moiety is presented with a particular emphasis on the practicality, robustness, and streamlining of the process.

  DOI：

  10.1021/op700222r

文献信息

• [EN] 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS<br/>[FR] DERIVES DU 5-PHENYLTHIAZOL ET LEURS UTILISATIONS COMME INHIBITEURS DE LA PI3 KINASE
  申请人：NOVARTIS AG

  公开号：WO2003072557A1

  公开（公告）日：2003-09-04

  Compounds of Formula I in free or salt form, wherein R1,R2,R3,R4, and R5, have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I中的化合物以自由或盐形式存在，其中R1、R2、R3、R4和R5的含义如规范中所示，适用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的过程。
• 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
  申请人：Bruce Ian

  公开号：US20050119320A1

  公开（公告）日：2005-06-02

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3、R4和R5的含义如规范中所示，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS
  申请人：Bruce Ian

  公开号：US20100093690A1

  公开（公告）日：2010-04-15

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3、R4和R5的含义如规范中所示，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases
  申请人：Bloomfield Graham Charles

  公开号：US20080280871A1

  公开（公告）日：2008-11-13

  in free or salt form, wherein R a , R b , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  在自由或盐形式中，其中Ra，Rb，R2，R3，R4和R5具有规范中指示的含义，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有该化合物的药物组合物以及制备该化合物的过程。
• 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylin ositol 3 kinase enzymes (PI13) for treatment of inflammatory diseases
  申请人：Novartis AG

  公开号：US07902375B2

  公开（公告）日：2011-03-08

  in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  本发明涉及一种以自由或盐形式存在的化合物，其中Ra、Rb、R2、R3、R4和R5在说明书中所示的含义，该化合物可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有该化合物的制药组合物以及制备该化合物的过程。